Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest
Open Access
- 15 December 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (12), 1603-1611
- https://doi.org/10.1086/508873
Abstract
Until recently, cardiac toxicity manifesting in the form of arrhythmias related to QT interval prolongation was uncommonly appreciated within the antimicrobial class of drugs, but it was well described among antiarrhythmic agents. Antimicrobials that are associated with QT prolongation include the macrolides/ketolides, certain fluoroquinolones and antimalarials, pentamidine, and the azole antifungals. Although, in most cases, mild delays in ventricular repolarization caused by these drugs are clinically unnoticable, they may serve to amplify the risk for torsades de pointes (TdP) when prescribed in the setting of other risk factors. Conditions or variables that influence proarrhythmic risk include sex, age, electrolyte derangements, structural heart disease, pharmacokinetic/pharmacodynamic interactions, and genetic predisposition. It is important that clinicians be knowledgable about drugs with QT liability, as well as the risk factors that increase the probability of TdP. Additionally, because TdP remains a difficult-to-measure adverse event, we must rely upon multiple data sources to determine the risk versus the benefit for newly approved drugs.Keywords
This publication has 79 references indexed in Scilit:
- Voriconazole Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2006
- Drugs, QTc Interval Prolongation and Final ICH E14 GuidelineDrug Safety, 2005
- Drug-Induced Prolongation of the QT IntervalThe New England Journal of Medicine, 2004
- Pharmacogenetic Aspects of Drug-Induced Torsade de PointesDrug Safety, 2004
- QT Prolongation with Antimicrobial AgentsDrugs, 2004
- Adverse Drug Reactions Related to the Use of Fluoroquinolone AntimicrobialsDrug Safety, 2003
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Systemic Antifungal AgentsDrug Safety, 1998
- Torsade de PointesDrugs, 1994